AU2013249337A1 - Neuroprotective composition and method of use - Google Patents

Neuroprotective composition and method of use Download PDF

Info

Publication number
AU2013249337A1
AU2013249337A1 AU2013249337A AU2013249337A AU2013249337A1 AU 2013249337 A1 AU2013249337 A1 AU 2013249337A1 AU 2013249337 A AU2013249337 A AU 2013249337A AU 2013249337 A AU2013249337 A AU 2013249337A AU 2013249337 A1 AU2013249337 A1 AU 2013249337A1
Authority
AU
Australia
Prior art keywords
peptide
polyarginine
polyarginine peptide
cysteines
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013249337A
Other languages
English (en)
Inventor
Dennis J. Goebel
John Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Brown University
Original Assignee
Wayne State University
Brown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Brown University filed Critical Wayne State University
Publication of AU2013249337A1 publication Critical patent/AU2013249337A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2013249337A 2012-04-17 2013-04-17 Neuroprotective composition and method of use Abandoned AU2013249337A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625349P 2012-04-17 2012-04-17
US61/625,349 2012-04-17
PCT/US2013/036938 WO2013158739A1 (en) 2012-04-17 2013-04-17 Neuroprotective composition and method of use

Publications (1)

Publication Number Publication Date
AU2013249337A1 true AU2013249337A1 (en) 2014-10-30

Family

ID=49384027

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013249337A Abandoned AU2013249337A1 (en) 2012-04-17 2013-04-17 Neuroprotective composition and method of use

Country Status (6)

Country Link
US (2) US20150126457A1 (enExample)
EP (1) EP2872160A4 (enExample)
JP (1) JP2015514771A (enExample)
AU (1) AU2013249337A1 (enExample)
CA (1) CA2870711A1 (enExample)
WO (1) WO2013158739A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2872160A4 (en) 2012-04-17 2015-11-25 Univ Brown NERVO-PROTECTING COMPOSITION AND USE METHOD
CN106170491B (zh) * 2013-10-30 2020-07-24 阿尔杰妮卡治疗学有限公司 神经保护肽
US20170114093A1 (en) * 2015-05-29 2017-04-27 Andrew Peter Mallon Methods of Treatment and Prevention of Disease by Arginine-rich Compositions that Induce Cytoprotection and Neuroprotection
US20210101935A1 (en) 2019-10-02 2021-04-08 Brown University Cyclic peptidomimetic for the treatment of neurological disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2210761T3 (es) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
JP2007526316A (ja) * 2004-03-01 2007-09-13 ルーメン セラピューティックス リミテッド ライアビリティ カンパニー 疾患を処置するための組成物および方法
US20130012447A1 (en) * 2007-08-27 2013-01-10 Eiketsu Sho Protein kinase c-delta inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation
JP5816550B2 (ja) * 2009-06-22 2015-11-18 株式会社メディネット 蛋白質の修飾剤
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
US20110053829A1 (en) * 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2872160A4 (en) 2012-04-17 2015-11-25 Univ Brown NERVO-PROTECTING COMPOSITION AND USE METHOD

Also Published As

Publication number Publication date
EP2872160A1 (en) 2015-05-20
EP2872160A4 (en) 2015-11-25
US20170107253A1 (en) 2017-04-20
WO2013158739A1 (en) 2013-10-24
CA2870711A1 (en) 2013-10-24
US20150126457A1 (en) 2015-05-07
US10040822B2 (en) 2018-08-07
JP2015514771A (ja) 2015-05-21

Similar Documents

Publication Publication Date Title
EP3615057B1 (en) Dosing regimen for treatment of cognitive impairments with blood plasma products
McManus et al. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders
US10040822B2 (en) Neuroprotective composition and method of use
US20060205822A1 (en) 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US20240041860A1 (en) Restoration of motor function post-neurological injury using psychedelics
US20240122897A1 (en) Dmt salts and their use to treat brain injury
EP4531850A1 (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
Dudin et al. Scorpion sting in children in the Jerusalem area: a review of 54 cases
GB2619119A (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
US20170304358A1 (en) Primary and secondary prevention of dementias and suicide with trace dose lithium
LEE et al. THE ANTIHISTAMINE ACTION OF N-(2-PYRIDYL)-N-(2-THENYL)-N', N'-DIMETHYLETHYLENEDIAMINE HYDROCHLORIDE
KR20250004041A (ko) 삼차 신경통 치료 및 그와 관련된 통증 감소에 사용하기 위한 트리메프라진
WO2018129231A1 (en) Method for treating multiple sclerosis
US9333207B2 (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cerebrovascular disease and neurodegenerative diseases of the central nervous system
CN111263637A (zh) 痴呆症的预防及/或治疗剂
WO2022094565A1 (en) N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders
CN113117090A (zh) 以胞内蛋白纳米颗粒渗透压为靶点治疗人体水肿的药物组合物及应用
US11759451B2 (en) Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury
CA3042013C (en) Pharmaceutical composition and method of treating female sexual dysfunctions
EP4719440A1 (en) Compositions of blood plasma fractions and blood plasma subfractions and their use in treatment of disease
Al-Humaidan et al. Can propofol cause dystonia and movement disorders?
US20240316143A1 (en) Therapeutic agents and/or pharmaceutical compositions for neurocognitive disorders
US8664209B2 (en) Daptomycin for multiple sclerosis
Raveena et al. Acute psychosis induced by topical cyclopentolate eye drops in a young child
Genis Neuroprotective Agents for Traumatic Brain Injury: Theoretical Therapy or the Future of Treatment?

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted